{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:23:03Z","timestamp":1790364183777,"version":"4.1.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11910-022-01247-x","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:07:56Z","timestamp":1669705676000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Neurological Complications Following COVID-19 Vaccination"],"prefix":"10.1007","volume":"23","author":[{"given":"Aparajita","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambar","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"1247_CR1","unstructured":"World Health Organization. Global vaccine action plan 2011\u20132020. WHO. https:\/\/www.who.int\/immunization\/global_vaccine_action_plan\/GVAP_doc_2011_2020\/en\/\u00a0(2013). Accessed Oct 2022."},{"key":"1247_CR2","unstructured":"World Health Organization. Child mortality and causes of death. WHO.\u00a0https:\/\/www.who.int\/gho\/child_health\/mortality\/mortality_under_five_text\/en\/ (2020). Accessed Oct 2022."},{"issue":"6494","key":"1247_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.abb8923","volume":"368","author":"BS Graham","year":"2020","unstructured":"Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945\u20136. https:\/\/doi.org\/10.1126\/science.abb8923.","journal-title":"Science"},{"issue":"2","key":"1247_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","volume":"28","author":"G Forni","year":"2021","unstructured":"Forni G, Mantovani A. COVID-19 Commission of Accademia Nazionale dei Lincei, Rome COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626\u201339. https:\/\/doi.org\/10.1038\/s41418-020-00720-9.","journal-title":"Cell Death Differ"},{"key":"1247_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21:83\u2013100. https:\/\/doi.org\/10.1038\/s41577-020-00479-7.","journal-title":"Nat Rev Immunol"},{"key":"1247_CR6","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"\u2022 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577. This article demonstrates the mechanism of action, safety and efficacy of the Pfizer-BioNTech vaccine against COVID19.","journal-title":"N Engl J Med"},{"key":"1247_CR7","doi-asserted-by":"publisher","unstructured":"\u2022 Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2\u2014 preliminary report. N Engl J Med Overseas Ed. 2020;383:1920\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2022483. This article discusses the mechanism of action and rate of adverse events of the Moderna vaccine against COVID19.","DOI":"10.1056\/NEJMoa2022483"},{"key":"1247_CR8","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"\u2022 Sadoff J, Gray G, Vandebosch A, C\u00e1rdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187\u2013201. https:\/\/doi.org\/10.1056\/NEJMoa2101544. This article elaborates on the mechanism of action, efficacy and adverse events with the Ad26.COV2.S vaccine.","journal-title":"N Engl J Med"},{"key":"1247_CR9","doi-asserted-by":"publisher","unstructured":"\u2022  Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia.\u00a0Lancet. 2020;396:887\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(20)31866-3. Article discussing the principle of the Sputnik V vaccine along with phase III trial data regarding efficacy and tolerability.","DOI":"10.1016\/S0140-6736(20)31866-3"},{"key":"1247_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"\u2022 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1. Article elucidating the phase II\/III clinical trial data regarding vaccine efficacy and adverse event profile in the Oxford\/ ChAdOx1 nCoV-19 vaccine.","journal-title":"Lancet"},{"issue":"13","key":"1247_CR11","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"\u2022 Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2107659. Data from Phase III trial of Novavax including protection offered and adverse event profile.","journal-title":"N Engl J Med"},{"issue":"10317","key":"1247_CR12","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","volume":"398","author":"R Ella","year":"2021","unstructured":"\u2022 Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)02000-6. This article elucidates the mechanism of action, and reports the efficacy and safety data of phase III trial with Covaxin.","journal-title":"Lancet"},{"key":"1247_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijid.2021.08.013","volume":"111","author":"BQ Saeed","year":"2021","unstructured":"\u2022 Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219\u201326. https:\/\/doi.org\/10.1016\/j.ijid.2021.08.013. This article reviews the adverse events reported with the Sinopharm vaccine use in the UAE.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"1247_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","volume":"21","author":"Z Wu","year":"2021","unstructured":"\u2022 Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. 2021;21(6):803\u201312. https:\/\/doi.org\/10.1016\/S1473-3099(20)30987-7. Article discussing potency and side effect profile of CoronaVac vaccine.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1247_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12291-021-00968-z","volume":"36","author":"RJ Kaur","year":"2021","unstructured":"\u2022\u2022 Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427\u201339. https:\/\/doi.org\/10.1007\/s12291-021-00968-z. This article provides a comprehensive review of the safety profile of the various licensed COVID19 vaccines.","journal-title":"Indian J Clin Biochem"},{"key":"1247_CR16","doi-asserted-by":"publisher","first-page":"876336","DOI":"10.3389\/fpubh.2022.876336","volume":"10","author":"S Ganesan","year":"2022","unstructured":"Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE-an observational study. Front Public Health. 2022;10:876336. https:\/\/doi.org\/10.3389\/fpubh.2022.876336.","journal-title":"Front Public Health"},{"key":"1247_CR17","doi-asserted-by":"publisher","first-page":"e069445","DOI":"10.1136\/bmj-2021-069445","volume":"378","author":"J Pillay","year":"2022","unstructured":"\u2022 Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ. 2022;378:e069445. https:\/\/doi.org\/10.1136\/bmj-2021-069445. Article reviews available data regarding development of myocarditis and pericarditis post-COVID vaccination and possible mechanism.","journal-title":"BMJ"},{"issue":"1","key":"1247_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10072-021-05662-9","volume":"43","author":"RK Garg","year":"2022","unstructured":"\u2022\u2022 Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022;43(1):3\u201340. https:\/\/doi.org\/10.1007\/s10072-021-05662-9. An exhaustive review of reported neurological adverse events with various COVID19 vaccines.","journal-title":"Neurol Sci"},{"key":"1247_CR19","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Garc\u00eda-Grimshaw M, Ceballos-Liceaga SE, Hern\u00e1ndez-Vanegas LE, N\u00fa\u00f1ez I, Hern\u00e1ndez-Valdivia N, Carrillo-Garc\u00eda DA, et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study. Clin Immunol. 2021;229:108786. https:\/\/doi.org\/10.1016\/j.clim.2021.108786. The article reports on the incidence of neurological adverse events post-vaccination with the first dose of Pfizer-BioNTech vaccine in a Mexican cohort.","DOI":"10.1016\/j.clim.2021.108786"},{"issue":"14","key":"1247_CR20","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.3346\/jkms.2021.36.e107","volume":"36","author":"SH Kim","year":"2021","unstructured":"Kim SH, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH, et al. Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: a single center experience. J Korean Med Sci. 2021;36(14):e107. https:\/\/doi.org\/10.3346\/jkms.2021.36.e107.","journal-title":"J Korean Med Sci"},{"issue":"21","key":"1247_CR21","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.3346\/jkms.2021.36.e153","volume":"36","author":"YW Lee","year":"2021","unstructured":"Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci. 2021;36(21):e153. https:\/\/doi.org\/10.3346\/jkms.2021.36.e153.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"1247_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s40122-021-00296-3","volume":"10","author":"CH G\u00f6bel","year":"2021","unstructured":"G\u00f6bel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. Headache attributed to vaccination against COVID-19 (coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study. Pain Ther. 2021;10(2):1309\u201330. https:\/\/doi.org\/10.1007\/s40122-021-00296-3.","journal-title":"Pain Ther"},{"issue":"1","key":"1247_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s10194-021-01324-5","volume":"22","author":"D Garc\u00eda-Azor\u00edn","year":"2021","unstructured":"\u2022 Garc\u00eda-Azor\u00edn D, Do TP, Gantenbein AR, Hansen JM, Souza MNP, Obermann M, et al. Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis. J Headache Pain. 2021;22(1):108. https:\/\/doi.org\/10.1186\/s10194-021-01324-5. This article provides strong evidence in favor of ruling out cerebral venous sinus thrombosis in patients with delayed onset headaches after adenoviral vaccines.","journal-title":"J Headache Pain"},{"key":"1247_CR24","unstructured":"World Health Organization. COVID-19 vaccines: safety surveillance manual. World Health Organization. 2020. https:\/\/apps.who.int\/iris\/handle\/10665\/338400. Accessed Oct 2022."},{"issue":"1","key":"1247_CR25","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1097\/CCM.0000000000005211","volume":"50","author":"T Iba","year":"2022","unstructured":"\u2022\u2022 Iba T, Levy JH, Warkentin TE. Recognizing vaccine-induced immune thrombotic thrombocytopenia. Crit Care Med. 2022;50(1):e80\u20136. https:\/\/doi.org\/10.1097\/CCM.0000000000005211. This article provides an extensive review of vaccine-induced thrombocytopenia following COVID19 vaccination.","journal-title":"Crit Care Med"},{"key":"1247_CR26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840","author":"A Greinacher","year":"2021","unstructured":"\u2022\u2022 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2104840. The authors of this study demonstrated their patients to test positive on a screening platelet factor 4 (PF4)-heparin immunoassay although none of them had received heparin in the past. Patients also tested positive on a platelet-activation assay in the presence of PF4 independent of heparin. Platelet activation was inhibited by high levels of heparin and immunoglobulin . It was postulated that \u201cthe vaccine resulted in a rare thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia (HIT)\u201d.","journal-title":"N Engl J Med"},{"issue":"23","key":"1247_CR27","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","volume":"384","author":"M Scully","year":"2021","unstructured":"\u2022\u2022 Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202\u201311. https:\/\/doi.org\/10.1056\/NEJMoa2105385. Case series of patients who developed thrombosis with thrombocytopenia and positive antibodies to platelet factor 4 after inoculation with AstraZeneca vaccine, providing insights into mechanism and outcomes.","journal-title":"N Engl J Med"},{"issue":"9","key":"1247_CR28","doi-asserted-by":"publisher","first-page":"e870","DOI":"10.1097\/CCM.0000000000005105","volume":"49","author":"S Bersinger","year":"2021","unstructured":"Bersinger S, Lagarde K, Marlu R, Pernod G, Payen JF. Using nonheparin anticoagulant to treat a near-fatal case with multiple venous thrombotic lesions during ChAdOx1 nCoV-19 vaccination-related vaccine-induced immune thrombotic thrombocytopenia. Crit Care Med. 2021;49(9):e870\u20133. https:\/\/doi.org\/10.1097\/CCM.0000000000005105.","journal-title":"Crit Care Med"},{"key":"1247_CR29","doi-asserted-by":"publisher","unstructured":"Graf T, Thiele T, Klingebiel R, Greinacher A, Sch\u00e4bitz WR, Greeve I. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus nvenous and portal vein thrombosis. J Neurol. 2021:20211\u20133. https:\/\/doi.org\/10.1007\/s00415-021-10599-2","DOI":"10.1007\/s00415-021-10599-2"},{"key":"1247_CR30","doi-asserted-by":"publisher","unstructured":"George G, Friedman KD, Curtis BR, Lind SE. Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination. Am J Hematol. 2021.\u00a0https:\/\/doi.org\/10.1002\/ajh.26237.","DOI":"10.1002\/ajh.26237"},{"issue":"4","key":"1247_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1182\/blood.2021011958","volume":"138","author":"A Tiede","year":"2021","unstructured":"Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood. 2021;138(4):350\u20133. https:\/\/doi.org\/10.1182\/blood.2021011958.","journal-title":"Blood"},{"issue":"4","key":"1247_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ana.26172","volume":"90","author":"JB Schulz","year":"2021","unstructured":"Schulz JB, Berlit P, Diener HC, Gerloff C, Greinacher A, Klein C, et al. COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. Ann Neurol. 2021;90(4):627\u201339. https:\/\/doi.org\/10.1002\/ana.26172.","journal-title":"Ann Neurol"},{"key":"1247_CR33","doi-asserted-by":"publisher","unstructured":"Gattringer T, Gressenberger P, Gary T, W\u00f6lfler A, Kneihsl M, Raggam RB.\u00a0Successful management of vaccine-induced immune thrombotic thrombocytopenia-related cerebral sinus venous thrombosis after ChAdOx1 nCov-19 vaccination. Stroke Vasc Neurol.svn-2021\u2013001142. 2021. https:\/\/doi.org\/10.1136\/svn-2021-001142","DOI":"10.1136\/svn-2021-001142"},{"issue":"4","key":"1247_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.annemergmed.2021.04.035","volume":"78","author":"RT Clark","year":"2021","unstructured":"Clark RT, Johnson L, Billotti J, Foulds G, Ketels T, Heard K, et al. Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination. Ann Emerg Med. 2021;78(4):511\u20134. https:\/\/doi.org\/10.1016\/j.annemergmed.2021.04.035.","journal-title":"Ann Emerg Med."},{"key":"1247_CR35","doi-asserted-by":"publisher","first-page":"n1114","DOI":"10.1136\/bmj.n1114","volume":"373","author":"A Potteg\u00e5rd","year":"2021","unstructured":"\u2022\u2022 Potteg\u00e5rd A, Lund LC, Karlstad \u00d8, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114. https:\/\/doi.org\/10.1136\/bmj.n1114. Study reporting arterial and hemostatic events after AstraZeneca vaccination in Denmark and Norway.","journal-title":"BMJ"},{"issue":"11","key":"1247_CR36","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1111\/ene.15029","volume":"28","author":"K Krzywicka","year":"2021","unstructured":"Krzywicka K, Heldner MR, S\u00e1nchez van Kammen M, van Haaps T, Hiltunen S, Silvis SM, et al. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. Eur J Neurol. 2021;28(11):3656\u201362. https:\/\/doi.org\/10.1111\/ene.15029.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1247_CR37","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1186\/s12879-021-06960-5","volume":"21","author":"PM McKeigue","year":"2021","unstructured":"McKeigue PM, Burgul R, Bishop J, Robertson C, McMenamin J, O\u2019Leary M, et al. Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland. BMC Infect Dis. 2021;21(1):1275. https:\/\/doi.org\/10.1186\/s12879-021-06960-5.","journal-title":"BMC Infect Dis"},{"issue":"10306","key":"1247_CR38","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(21)01608-1","volume":"398","author":"RJ Perry","year":"2021","unstructured":"Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet. 2021;398(10306):1147\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(21)01608-1.","journal-title":"Lancet"},{"key":"1247_CR39","unstructured":"\u2022 Chakravarty A. Between the devil and the deep blue sea? Case 3.14. In: Jaypee CA, editor. Neurology & Internal Medicine \u2013 A Case Based Study. New Delhi, London: Brothers Publications;\u00a02021, p. 195\u201399. Report of a case of cerebral venous sinus thrombosis in a lady following Covisheild COVID 19 vaccination . The patient had an underlying Protein S deficiency and hence had been put on oral anticoagulation for indefinite period."},{"key":"1247_CR40","unstructured":"\u2022\u2022 Covid-19 rapid guideline: Vaccine-induced immune thrombocytopenia and thrombosis (VITT) [Internet]. National Center for Biotechnology Information. U.S. National Library of Medicine; [cited 2022Nov6]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34406720\/. Accessed Nov 2022. NICE guidelines for the diagnosis and management of VITT."},{"issue":"9","key":"1247_CR41","doi-asserted-by":"publisher","first-page":"e870","DOI":"10.1097\/CCM.0000000000005105","volume":"49","author":"S Bersinger","year":"2021","unstructured":"Bersinger S, Lagarde K, Marlu R, Pernod G, Payen JF. Using nonheparin anticoagulant to treat a near-fatal case with multiple venous thrombotic lesions during ChAdOx1 nCoV-19 vaccination-related vaccine-induced immune thrombotic thrombocytopenia. Crit Care Med. 2021;49(9):e870\u20133. https:\/\/doi.org\/10.1097\/CCM.0000000000005105.","journal-title":"Crit Care Med"},{"issue":"6","key":"1247_CR42","doi-asserted-by":"publisher","first-page":"106440","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106440","volume":"31","author":"M Kakovan","year":"2022","unstructured":"\u2022 Kakovan M, Ghorbani Shirkouhi S, Zarei M, Andalib S. Stroke Associated with COVID-19 Vaccines. J Stroke Cerebrovasc Dis. 2022;31(6):106440. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2022.106440. This article analyses data regarding strokes associated with COVID vaccination.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"7","key":"1247_CR43","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1111\/jth.15347","volume":"19","author":"RA Blauenfeldt","year":"2021","unstructured":"Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ, Hvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost. 2021;19(7):1771\u20135. https:\/\/doi.org\/10.1111\/jth.15347.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1247_CR44","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1038\/s41467-021-25010-x","volume":"12","author":"M De Michele","year":"2021","unstructured":"De Michele M, Iacobucci M, Chistolini A, Nicolini E, Pulcinelli F, Cerbelli B, et al. Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia. Nat Commun. 2021;12(1):4663. https:\/\/doi.org\/10.1038\/s41467-021-25010-x.","journal-title":"Nat Commun"},{"issue":"11","key":"1247_CR45","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1136\/jnnp-2021-326984","volume":"92","author":"T Al-Mayhani","year":"2021","unstructured":"Al-Mayhani T, Saber S, Stubbs MJ, Losseff NA, Perry RJ, Simister RJ, et al. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. J Neurol Neurosurg Psychiatry. 2021;92(11):1247\u20138. https:\/\/doi.org\/10.1136\/jnnp-2021-326984.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1247_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-022-01385-0","volume":"23","author":"NC Suwanwela","year":"2022","unstructured":"\u2022 Suwanwela NC, Kijpaisalratana N, Tepmongkol S, et al. Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series. J Headache Pain. 2022;23(1):13. https:\/\/doi.org\/10.1186\/s10194-022-01385-0. Case series of a novel transient neurological phenomenon resembling prolonged migraine aura post administration of CoronaVac.","journal-title":"J Headache Pain."},{"key":"1247_CR47","doi-asserted-by":"publisher","unstructured":"Bj\u00f8rnstad-Tuveng TH, Rudjord A, Anker P.\u00a0Fatal cerebral haemorrhage after COVID-19 vaccine. Fatal hjernebl\u00f8dning etter covid-19-vaksine.\u00a0Tidsskr Nor Laegeforen. 2021;141. https:\/\/doi.org\/10.4045\/tidsskr.21.0312","DOI":"10.4045\/tidsskr.21.0312"},{"key":"1247_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13505","author":"ML de Melo Silva","year":"2021","unstructured":"de Melo Silva ML, Lopes DP. Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report. Acta Neurol Scand. 2021. https:\/\/doi.org\/10.1111\/ane.13505.","journal-title":"Acta Neurol Scand"},{"key":"1247_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.hest.2021.06.001","volume":"2","author":"J Finsterer","year":"2021","unstructured":"Finsterer J, Korn M. Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine. Brain Hemorrhages. 2021;2:165\u20137. https:\/\/doi.org\/10.1016\/j.hest.2021.06.001.","journal-title":"Brain Hemorrhages"},{"issue":"34","key":"1247_CR50","doi-asserted-by":"publisher","first-page":"E1341","DOI":"10.1503\/cmaj.211212","volume":"193","author":"J Robichaud","year":"2021","unstructured":"Robichaud J, C\u00f4t\u00e9 C, C\u00f4t\u00e9 F. Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford-AstraZeneca) vaccination. CMAJ. 2021;193(34):E1341\u20134. https:\/\/doi.org\/10.1503\/cmaj.211212.","journal-title":"CMAJ"},{"issue":"2","key":"1247_CR51","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000523769.PMID:35702446;PMCID:PMC9149540","volume":"14","author":"M Rosso","year":"2022","unstructured":"Rosso M, Anziska Y, Levine SR. Acute transient encephalopathy after Moderna COVID-19 vaccine. Case Rep Neurol. 2022;14(2):231\u20136. https:\/\/doi.org\/10.1159\/000523769.PMID:35702446;PMCID:PMC9149540.","journal-title":"Case Rep Neurol"},{"issue":"7","key":"1247_CR52","doi-asserted-by":"publisher","first-page":"e16172","DOI":"10.7759\/cureus.16172","volume":"13","author":"BD Liu","year":"2021","unstructured":"\u2022 Liu BD, Ugolini C, Jha P. Two cases of post-Moderna COVID-19 vaccine encephalopathy associated with nonconvulsive status epilepticus. Cureus. 2021;13(7):e16172. https:\/\/doi.org\/10.7759\/cureus.16172. Case reports of new onset encephalopathy with non-convulsive status epilepticus following administration of the Moderna vaccine.","journal-title":"Cureus"},{"key":"1247_CR53","doi-asserted-by":"publisher","first-page":"102803","DOI":"10.1016\/j.amsu.2021.102803","volume":"69","author":"AF Al-Mashdali","year":"2021","unstructured":"Al-Mashdali AF, Ata YM, Sadik N. Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: a case report. Ann Med Surg (Lond). 2021;69:102803. https:\/\/doi.org\/10.1016\/j.amsu.2021.102803.","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"1247_CR54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12024-021-00440-7","volume":"18","author":"F Permezel","year":"2022","unstructured":"\u2022\u2022 Permezel F, Borojevic B, Lau S, de Boer HH. Acute disseminated encephalomyelitis (ADEM) following recent Oxford\/AstraZeneca COVID-19 vaccination. Forensic Sci Med Pathol. 2022;18(1):74\u20139. https:\/\/doi.org\/10.1007\/s12024-021-00440-7. This article summarizes the clinical features and autopsy findings of the first fatal case of ADEM following Oxford\/AstraZeneca vaccine.","journal-title":"Forensic Sci Med Pathol"},{"issue":"4","key":"1247_CR55","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s13760-021-01699-x","volume":"121","author":"G OzgenKenangil","year":"2021","unstructured":"OzgenKenangil G, Ari BC, Guler C, Demir MK. Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine [published correction appears in Acta Neurol Belg. Acta Neurol Belg. 2021;121(4):1089\u201391. https:\/\/doi.org\/10.1007\/s13760-021-01699-x.","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"1247_CR56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13760-021-01608-2","volume":"122","author":"L Cao","year":"2022","unstructured":"Cao L, Ren L. Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. Acta Neurol Belg. 2022;122(3):793\u20135. https:\/\/doi.org\/10.1007\/s13760-021-01608-2.","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"1247_CR57","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/ana.26182","volume":"90","author":"F Zuhorn","year":"2021","unstructured":"\u2022\u2022 Zuhorn F, Graf T, Klingebiel R, Sch\u00e4bitz WR, Rogalewski A. Postvaccinal Encephalitis after ChAdOx1 nCov-19. Ann Neurol. 2021;90(3):506\u201311. https:\/\/doi.org\/10.1002\/ana.26182. Case series of 23 patients with post-vaccinal encephalitis fulfilling the criteria for autoimmune encephalitis after vaccination with the Oxford\/AstraZeneca vaccine.","journal-title":"Ann Neurol"},{"issue":"7","key":"1247_CR58","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jiac.2022.02.009","volume":"28","author":"Y Kobayashi","year":"2022","unstructured":"Kobayashi Y, Karasawa S, Ohashi N, Yamamoto K. A case of encephalitis following COVID-19 vaccine. J Infect Chemother. 2022;28(7):975\u20137. https:\/\/doi.org\/10.1016\/j.jiac.2022.02.009.","journal-title":"J Infect Chemother"},{"key":"1247_CR59","doi-asserted-by":"publisher","first-page":"872734","DOI":"10.3389\/fneur.2022.872734","volume":"13","author":"MR Bensaidane","year":"2022","unstructured":"Bensaidane MR, Picher-Martel V, \u00c9mond F, De Serres G, Dupr\u00e9 N, Beauchemin P. Case report: Acute necrotizing encephalopathy following COVID-19 vaccine. Front Neurol. 2022;13:872734. https:\/\/doi.org\/10.3389\/fneur.2022.872734.","journal-title":"Front Neurol"},{"key":"1247_CR60","doi-asserted-by":"publisher","unstructured":"Malhotra SH, Gupta P, Prabhu V, Garg RK, Dandu H, Agarwal V. COVID-19 vaccination-associated myelitis. QJM. 2021;hcab069. https:\/\/doi.org\/10.1093\/qjmed\/hcab069","DOI":"10.1093\/qjmed\/hcab069"},{"issue":"1","key":"1247_CR61","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12883-021-02427-x","volume":"21","author":"WY Tan","year":"2021","unstructured":"Tan WY, Yusof Khan AHK, MohdYaakob MN, Abdul Rashid AM, Loh WC, Baharin J, et al. Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: a case report. BMC Neurol. 2021;21(1):395. https:\/\/doi.org\/10.1186\/s12883-021-02427-x.","journal-title":"BMC Neurol."},{"key":"1247_CR62","doi-asserted-by":"publisher","first-page":"577606","DOI":"10.1016\/j.jneuroim.2021.577606","volume":"358","author":"C Pagenkopf","year":"2021","unstructured":"Pagenkopf C, S\u00fcdmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J Neuroimmunol. 2021;358:577606. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577606.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"1247_CR63","doi-asserted-by":"publisher","first-page":"JC29","DOI":"10.7326\/ACPJ202103160-029","volume":"174","author":"Z Chagla","year":"2021","unstructured":"Chagla Z. In adults, the Oxford\/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose. Ann Intern Med. 2021;174(3):JC29. https:\/\/doi.org\/10.7326\/ACPJ202103160-029.","journal-title":"Ann Intern Med"},{"issue":"10269","key":"1247_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","volume":"397","author":"MD Knoll","year":"2021","unstructured":"Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(20)32623-4.","journal-title":"Lancet"},{"issue":"12","key":"1247_CR65","doi-asserted-by":"publisher","first-page":"653786","DOI":"10.3389\/fimmu.2021.653786.PMID:33981305;PMCID:PMC8107358","volume":"26","author":"GC Rom\u00e1n","year":"2021","unstructured":"Rom\u00e1n GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol. 2021;26(12):653786. https:\/\/doi.org\/10.3389\/fimmu.2021.653786.PMID:33981305;PMCID:PMC8107358.","journal-title":"Front Immunol"},{"key":"1247_CR66","doi-asserted-by":"publisher","first-page":"897275","DOI":"10.3389\/fneur.2022.897275","volume":"13","author":"C Quintanilla-Bord\u00e1s","year":"2022","unstructured":"\u2022 Quintanilla-Bord\u00e1s C, Gasc\u00f3n-Gimenez F, Alcal\u00e1 C, Pay\u00e1 M, Mallada J, Silla R, et al. Case report: Exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: a case series. Front Neurol. 2022;13:897275. https:\/\/doi.org\/10.3389\/fneur.2022.897275. Case series of patients with yet-unrecognized multiple sclerosis whose relapses flared with mRNA vaccines and possible mechanisms and immune markers.","journal-title":"Front Neurol"},{"key":"1247_CR67","doi-asserted-by":"publisher","first-page":"103433","DOI":"10.1016\/j.msard.2021.103433","volume":"57","author":"S Epstein","year":"2022","unstructured":"\u2022\u2022 Epstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, et al. Vaccination against SARS-CoV-2 in neuroinflammatory disease: early safety\/tolerability data. Mult Scler Relat Disord. 2022;57:103433. https:\/\/doi.org\/10.1016\/j.msard.2021.103433. A large cross-sectional study demonstrating the safety of vaccination in patients with neuroimmunological disorders.","journal-title":"Mult Scler Relat Disord"},{"key":"1247_CR68","doi-asserted-by":"publisher","first-page":"103827","DOI":"10.1016\/j.msard.2022.103827","volume":"63","author":"A Dinoto","year":"2022","unstructured":"Dinoto A, Gastaldi M, Iorio R, Marini S, Damato V, Farina A, et al. Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders. Mult Scler Relat Disord. 2022;63:103827. https:\/\/doi.org\/10.1016\/j.msard.2022.103827.","journal-title":"Mult Scler Relat Disord"},{"key":"1247_CR69","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajem.2021.02.011","volume":"49","author":"M Alfishawy","year":"2021","unstructured":"Alfishawy M, Bitar Z, Elgazzar A, Elzoueiry M. Neuroleptic malignant syndrome following COVID-19 vaccination. Am J Emerg Med. 2021;49:408\u20139. https:\/\/doi.org\/10.1016\/j.ajem.2021.02.011.","journal-title":"Am J Emerg Med."},{"issue":"3","key":"1247_CR70","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s43678-021-00254-0","volume":"24","author":"T Nagamine","year":"2022","unstructured":"Nagamine T. Neuroleptic malignant syndrome associated with COVID-19 vaccination. CJEM. 2022;24(3):349\u201350. https:\/\/doi.org\/10.1007\/s43678-021-00254-0.","journal-title":"CJEM"},{"issue":"3","key":"1247_CR71","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.dsx.2021.05.003","volume":"15","author":"R Ghosh","year":"2021","unstructured":"Ghosh R, Dubey S, Roy D, Mandal A, Naga D, Benito-Le\u00f3n J. Focal onset non-motor seizure following COVID-19 vaccination: a mere coincidence? Diabetes Metab Syndr. 2021;15(3):1023\u20134. https:\/\/doi.org\/10.1016\/j.dsx.2021.05.003.","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"1247_CR72","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/JCP.0000000000001488","volume":"41","author":"AT Makhlouf","year":"2021","unstructured":"Makhlouf AT, Van Alphen MU, Manzano GS, Freudenreich O. A seizure after COVID-19 vaccination in a patient on clozapine. J Clin Psychopharmacol. 2021;41(6):689\u201390. https:\/\/doi.org\/10.1097\/JCP.0000000000001488.","journal-title":"J Clin Psychopharmacol"},{"key":"1247_CR73","doi-asserted-by":"publisher","first-page":"946644","DOI":"10.3389\/fneur.2022.946644","volume":"13","author":"J Werner","year":"2022","unstructured":"\u2022 Werner J, Brandi G, Jelcic I, Galovic M. New-onset refractory status epilepticus due to autoimmune encephalitis after vaccination against SARS-CoV-2: first case report. Front Neurol. 2022;13:946644. https:\/\/doi.org\/10.3389\/fneur.2022.946644. Case report of new-onset refractory status epilepticus with seronegative autoimmune encephalitis after Pfizer\/BioNTech vaccine.","journal-title":"Front Neurol."},{"key":"1247_CR74","doi-asserted-by":"publisher","first-page":"108808","DOI":"10.1016\/j.yebeh.2022.10880","volume":"134","author":"I Martinez-Fernandez","year":"2022","unstructured":"\u2022\u2022 Martinez-Fernandez I, Sanchez-Larsen A, Gonzalez-Villar E, Mart\u00ednez-Mart\u00edn \u00c1, von Quednow E, Del Valle-P\u00e9rez JA, et al. Observational retrospective analysis of vaccination against SARS-CoV-2 and seizures: VACCI-COVID registry. Epilepsy Behav. 2022;134:108808. https:\/\/doi.org\/10.1016\/j.yebeh.2022.10880. Retrospective study demonstrating the overall safety of COVID vaccines in patients with epilepsy.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"1247_CR75","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1007\/s10072-022-05956-6","volume":"43","author":"HN \u00d6zdemir","year":"2022","unstructured":"\u2022 \u00d6zdemir HN, Dere B, G\u00f6k\u00e7ay F, G\u00f6k\u00e7ay A. Are COVID-19 vaccines safe for people with epilepsy? A cross-sectional study Neurol Sci. 2022;43(6):3489\u201396. https:\/\/doi.org\/10.1007\/s10072-022-05956-6. Cross-sectional study showing that COVID vaccines are well tolerated in patients with epilepsy.","journal-title":"A cross-sectional study Neurol Sci"},{"key":"1247_CR76","doi-asserted-by":"publisher","first-page":"108160","DOI":"10.1016\/j.yebeh.2021.108160","volume":"122","author":"R von Wrede","year":"2021","unstructured":"von Wrede R, Pukropski J, Moskau-Hartmann S, Surges R, Baumgartner T. COVID-19 vaccination in patients with epilepsy: First experiences in a German tertiary epilepsy center. Epilepsy Behav. 2021;122:108160. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108160.","journal-title":"Epilepsy Behav"},{"key":"1247_CR77","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.seizure.2021.08.001","volume":"92","author":"F Massoud","year":"2021","unstructured":"Massoud F, Ahmad SF, Hassan AM, Alexander KJ, Al-Hashel J, Arabi M. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): a cross-sectional study. Seizure. 2021;92:2\u20139. https:\/\/doi.org\/10.1016\/j.seizure.2021.08.001.","journal-title":"Seizure"},{"key":"1247_CR78","doi-asserted-by":"publisher","first-page":"778618","DOI":"10.3389\/fneur.2021.778618","volume":"2","author":"N Li","year":"2021","unstructured":"Li N, Chu C, Lin W. A survey of hesitancy and response to the COVID-19 vaccine among patients with epilepsy in northeast China. Front Neurol. 2021;2:778618. https:\/\/doi.org\/10.3389\/fneur.2021.778618.","journal-title":"Front Neurol"},{"key":"1247_CR79","doi-asserted-by":"publisher","first-page":"108258","DOI":"10.1016\/j.yebeh.2021.108258","volume":"124","author":"LM Clayton","year":"2021","unstructured":"\u2022 Clayton LM, Balestrini S, Cross JH, Wilson G, Eldred C, Evans H, et al. The impact of SARS-COV-2 vaccination in Dravet syndrome: a UK survey. Epilepsy Behav. 2021;124:108258. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108258. This article provides data supporting the safety of COVID vaccination in patients with Dravet Syndrome.","journal-title":"Epilepsy Behav"},{"key":"1247_CR80","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2022.05.010","volume":"99","author":"Q Lu","year":"2022","unstructured":"Lu Q, Wang YY, Wang QH, Tang LN, Yang XY, Dun S, et al. Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin. Seizure. 2022;99:71\u20134. https:\/\/doi.org\/10.1016\/j.seizure.2022.05.010.","journal-title":"Seizure"},{"issue":"3","key":"1247_CR81","first-page":"143","volume":"23","author":"A Shemer","year":"2021","unstructured":"Shemer A, Pras E, Hecht I. Peripheral facial nerve palsy following BNT162b2 (COVID-19) vaccination. Isr Med Assoc J. 2021;23(3):143\u20134 (PMID: 33734623).","journal-title":"Isr Med Assoc J"},{"issue":"7","key":"1247_CR82","doi-asserted-by":"publisher","first-page":"e243829","DOI":"10.1136\/bcr-2021-243829","volume":"14","author":"A Burrows","year":"2021","unstructured":"Burrows A, Bartholomew T, Rudd J, Walker D. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. BMJ Case Rep. 2021;14(7):e243829. https:\/\/doi.org\/10.1136\/bcr-2021-243829.","journal-title":"BMJ Case Rep"},{"issue":"11","key":"1247_CR83","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1007\/s10072-021-05496-5","volume":"42","author":"M Obermann","year":"2021","unstructured":"Obermann M, Krasniqi M, Ewers N, Fayad J, Haeberle U. Bell\u2019s palsy following COVID-19 vaccination with high CSF antibody response. Neurol Sci. 2021;42(11):4397\u20139. https:\/\/doi.org\/10.1007\/s10072-021-05496-5.","journal-title":"Neurol Sci"},{"issue":"8","key":"1247_CR84","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoto.2021.1259","volume":"147","author":"A Shemer","year":"2021","unstructured":"Shemer A, Pras E, Einan-Lifshitz A, Dubinsky-Pertzov B, Hecht I. Association of COVID-19 vaccination and facial nerve palsy: a case-control study. JAMA Otolaryngol Head Neck Surg. 2021;147(8):739\u201343. https:\/\/doi.org\/10.1001\/jamaoto.2021.1259.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"1247_CR85","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1473-3099(21)00076-1","volume":"21","author":"A Ozonoff","year":"2021","unstructured":"\u2022\u2022 Ozonoff A, Nanishi E, Levy O. Bell\u2019s palsy and SARSCoV-2 vaccines. Lancet Infect Dis. 2021;21(4):450\u20132. https:\/\/doi.org\/10.1016\/S1473-3099(21)00076-1. This article reviews data regarding Bell\u2019s Palsy post-COVID vaccination demonstrating the increased risk of the same.","journal-title":"Lancet Infect Dis"},{"key":"1247_CR86","doi-asserted-by":"publisher","unstructured":"Lechien JR, Diallo AO, Dachy B, Le Bon SD, Maniaci A, Vaira LA, Saussez S (2021) COVID-19: Post-vaccine smell and taste disorders: report of 6 cases. Ear Nose Throat J Sep 1:1455613211033125. https:\/\/doi.org\/10.1177\/01455613211033125. Epub ahead of print. PMID: 34467793.","DOI":"10.1177\/01455613211033125"},{"issue":"3","key":"1247_CR87","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/RMR.0000000000000287","volume":"30","author":"G Keir","year":"2021","unstructured":"Keir G, Maria NI, Kirsch CFE. Unique imaging findings of neurologic phantosmia following Pfizer-BioNtech COVID-19 vaccination: a case report. Top Magn Reson Imaging. 2021;30(3):133\u20137. https:\/\/doi.org\/10.1097\/RMR.0000000000000287.","journal-title":"Top Magn Reson Imaging"},{"issue":"5","key":"1247_CR88","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaapos.2021.05.003","volume":"25","author":"DP Reyes-Capo","year":"2021","unstructured":"Reyes-Capo DP, Stevens SM, Cavuoto KM. Acute abducens nerve palsy following COVID-19 vaccination. J AAPOS. 2021;25(5):302\u20133. https:\/\/doi.org\/10.1016\/j.jaapos.2021.05.003.","journal-title":"J AAPOS"},{"issue":"12","key":"1247_CR89","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.4103\/ijo.IJO_2824_21","volume":"69","author":"M Sen","year":"2021","unstructured":"Sen M, Honavar SG. After the storm: ophthalmic manifestations of COVID-19 vaccines. Indian J Ophthalmol. 2021;69(12):3398\u2013420. https:\/\/doi.org\/10.4103\/ijo.IJO_2824_21.","journal-title":"Indian J Ophthalmol"},{"issue":"7","key":"1247_CR90","doi-asserted-by":"publisher","first-page":"e16791","DOI":"10.7759\/cureus.16791","volume":"13","author":"TY Chuang","year":"2021","unstructured":"Chuang TY, Burda K, Teklemariam E, Athar K. Tolosa-Hunt syndrome presenting after COVID-19 vaccination. Cureus. 2021;13(7):e16791. https:\/\/doi.org\/10.7759\/cureus.16791.","journal-title":"Cureus"},{"key":"1247_CR91","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1007\/s10792-021-01971-2","volume":"41","author":"AA Bialasiewicz","year":"2021","unstructured":"Bialasiewicz AA, Farah-Diab MS, Mebarki HT. Central retinal vein occlusion occurring immediately after 2nd dose of mRNA SARS-CoV-2 vaccine. Int Ophthalmol. 2021;41:3889\u201392. https:\/\/doi.org\/10.1007\/s10792-021-01971-2.","journal-title":"Int Ophthalmol"},{"key":"1247_CR92","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3889990","author":"LM Alvarez","year":"2021","unstructured":"\u2022\u2022 Alvarez LM, NingNeo Y, Davagnanam I, Ashenhurst M, Acheson J, Abdel-Hay A, et al. Post vaccination optic neuritis: Observations from the SARS-CoV-2 pandemic. SSRN Electron J. 2021. https:\/\/doi.org\/10.2139\/ssrn.3889990. Review article studying risk of optic neuritis post-vaccination, concluding that no definite increase in rates of optic neuritis after inoculation.","journal-title":"SSRN Electron J"},{"issue":"4","key":"1247_CR93","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamaoto.2021.4414","volume":"148","author":"EJ Formeister","year":"2022","unstructured":"Formeister EJ, Wu MJ, Chari DA, Meek R 3rd, Rauch SD, Remenschneider AK, et al. Assessment of sudden sensorineural hearing loss after COVID-19 vaccination. JAMA Otolaryngol Head Neck Surg. 2022;148(4):307\u201315. https:\/\/doi.org\/10.1001\/jamaoto.2021.4414.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"2","key":"1247_CR94","doi-asserted-by":"publisher","first-page":"e13426","DOI":"10.7759\/cureus.13426","volume":"13","author":"S Waheed","year":"2021","unstructured":"Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological Complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13(2):e13426. https:\/\/doi.org\/10.7759\/cureus.13426.","journal-title":"Cureus"},{"key":"1247_CR95","doi-asserted-by":"publisher","unstructured":"\u2022 M\u00e1rquez Loza AM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain-Barr\u00e9 syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000011881. Study of risk of GBS post-COVID vaccination demonstrating the absence of sufficient evidence to implicate vaccines as the cause.","DOI":"10.1212\/WNL.0000000000011881"},{"key":"1247_CR96","doi-asserted-by":"publisher","unstructured":"Kohli S, Varshney M, Mangla S, Jaiswal B, Chhabra PH. Guillain-Barr\u00e9 syndrome after COVID-19 vaccine: should we assume a causal link? International Journal of Medical and Pharmaceutical Case Reports. 2021;20\u20134. https:\/\/doi.org\/10.9734\/ijmpcr\/2021\/v14i130124.","DOI":"10.9734\/ijmpcr\/2021\/v14i130124"},{"issue":"3","key":"1247_CR97","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/jnnp-2021-327027","volume":"93","author":"GB Bonifacio","year":"2021","unstructured":"Bonifacio GB, Patel D, Cook S, Purcaru E, Couzins M, Domjan J, et al. Bilateral facial weakness with paraesthesia variant of Guillain-Barr\u00e9 syndrome following Vaxzevria COVID-19 vaccine. J Neurol Neurosurg Psychiatry. 2021;93(3):341\u20132. https:\/\/doi.org\/10.1136\/jnnp-2021-327027.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1247_CR98","doi-asserted-by":"publisher","first-page":"e244125","DOI":"10.1136\/bcr-2021-244125","volume":"14","author":"N McKean","year":"2021","unstructured":"McKean N, Chircop C. Guillain-Barr\u00e9 syndrome after COVID-19 vaccination. BMJ Case Rep. 2021;14(7):e244125. https:\/\/doi.org\/10.1136\/bcr-2021-244125.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"1247_CR99","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/mus.27251","volume":"64","author":"W Waheed","year":"2021","unstructured":"Waheed W, Carey ME, Tandan SR, Tandan R. Post COVID-19 vaccine small fiber neuropathy. Muscle Nerve. 2021;64(1):E1\u20132. https:\/\/doi.org\/10.1002\/mus.27251.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1247_CR100","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1002\/mus.27255","volume":"64","author":"S Mahajan","year":"2021","unstructured":"Mahajan S, Zhang F, Mahajan A, Zimnowodzki S. Parsonage Turner syndrome after COVID-19 vaccination. Muscle Nerve. 2021;64(1):E3\u20134. https:\/\/doi.org\/10.1002\/mus.27255.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1247_CR101","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","volume":"85","author":"DE McMahon","year":"2021","unstructured":"McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.092.","journal-title":"J Am Acad Dermatol"},{"key":"1247_CR102","doi-asserted-by":"publisher","unstructured":"\u2022 Nassar M, Chung H, Dhayaparan Y, Nyein A, Acevedo BJ, Chicos C, Zheng D, Barras M, Mohamed M, Alfishawy M, Nso N, Rizzo V, Kimball E. COVID-19 vaccine induced rhabdomyolysis: Case report with literature review. Diabetes Metab Syndr. 2021;15(4):102170. https:\/\/doi.org\/10.1016\/j.dsx.2021.06.007. Case report of possible vaccine-induced rhabdomyolysis with good outcome following prompt treatment.","DOI":"10.1016\/j.dsx.2021.06.007"},{"issue":"6","key":"1247_CR103","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/vaccines10060935","volume":"10","author":"M Kimura","year":"2022","unstructured":"Kimura M, Niwa JI, Doyu M. Recurring weakness in rhabdomyolysis following Pfizer-BioNTech coronavirus disease 2019 mRNA vaccination. Vaccines (Basel). 2022;10(6):935. https:\/\/doi.org\/10.3390\/vaccines10060935.","journal-title":"Vaccines (Basel)"},{"key":"1247_CR104","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Sansone G, Bonifati DM. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients. J Neurol. 2022;269:3965\u201381. https:\/\/doi.org\/10.1007\/s00415-022-11140-9. This review article examines the available data regarding safety of COVID vaccines in myasthenia patients.","DOI":"10.1007\/s00415-022-11140-9"},{"issue":"1","key":"1247_CR105","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/mds.28851","volume":"37","author":"C Cosentino","year":"2022","unstructured":"Cosentino C, Torres L, V\u00e9lez M, et al. SARS-CoV-2 vaccines and motor symptoms in Parkinson\u2019s disease. Mov Disord. 2022;37(1):233. https:\/\/doi.org\/10.1002\/mds.28851.","journal-title":"Mov Disord"},{"issue":"10","key":"1247_CR106","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1002\/mds.28772","volume":"36","author":"R Erro","year":"2021","unstructured":"Erro R, Buonomo AR, Barone P, Pellecchia MT. Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson\u2019s disease. Mov Disord. 2021;36(10):2219. https:\/\/doi.org\/10.1002\/mds.28772.","journal-title":"Mov Disord"},{"key":"1247_CR107","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1007\/s10072-022-06182-w","volume":"43","author":"G Imbalzano","year":"2022","unstructured":"\u2022\u2022 Imbalzano G, Ledda C, Artusi CA, Romagnolo A, Montanaro E, Rizzone MG, et al. SARS-CoV-2 vaccination, Parkinson\u2019s disease, and other movement disorders: case series and short literature review. Neurol Sci. 2022;43:5165\u20138. https:\/\/doi.org\/10.1007\/s10072-022-06182-w. Case report and review of other cases of Parkinsonism showing transient worsening of motor symptoms following COVID vaccination.","journal-title":"Neurol Sci"},{"issue":"5","key":"1247_CR108","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/psyg.12747","volume":"21","author":"MI Naharci","year":"2021","unstructured":"\u2022 Naharci MI, Tasci I. Delirium in a patient with Alzheimer\u2019s dementia following COVID-19 vaccination. Psychogeriatrics. 2021;21(5):846\u20137. https:\/\/doi.org\/10.1111\/psyg.12747. Case report of precipitation of delirium in a patient with Alzheimer\u2019s disease after CoronaVac Vaccine.","journal-title":"Psychogeriatrics"},{"issue":"2","key":"1247_CR109","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ana.26160","volume":"90","author":"JH Ng","year":"2021","unstructured":"Ng JH, Chaudhuri KR, Tan EK. Functional neurological disorders and COVID-19 vaccination. Ann Neurol. 2021;90(2):328. https:\/\/doi.org\/10.1002\/ana.26160.","journal-title":"Ann Neurol"},{"key":"1247_CR110","doi-asserted-by":"publisher","unstructured":"Takahashi O, Sakakibara R, Sawai S, Ogata T.\u00a0Functional neurological disorders after COVID-19 vaccination: Case series and literature review. Psychiatry Clin Neurosci. 2022;25. https:\/\/doi.org\/10.1111\/pcn.13453.","DOI":"10.1111\/pcn.13453"},{"issue":"7","key":"1247_CR111","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaneurol.2021.1042","volume":"78","author":"DD Kim","year":"2021","unstructured":"Kim DD, Kung CS, Perez DL. Helping the public understand adverse events associated with covid-19 vaccinations. JAMA Neurol. 2021;78(7):789. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1042.","journal-title":"JAMA Neurol"},{"key":"1247_CR112","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Butler M, Coebergh J, Safavi F, Carson A, Hallett M, Michael B, et al. 2021 Functional neurological disorder after SARS-CoV-2 vaccines: two case reports and discussion of potential public health implications. J Neuropsychiatry Clin Neurosci.\u00a0https:\/\/doi.org\/10.1176\/appi.neuropsych.21050116. Reports of patients developing functional neurological disorder following COVID-vaccination and implications.","DOI":"10.1176\/appi.neuropsych.21050116"},{"key":"1247_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10072-021-05504-8","volume":"42","author":"T Ercoli","year":"2021","unstructured":"Ercoli T, Lutzoni L, Orofino G, Muroni A, Defazio G. Functional neurological disorder after COVID-19 vaccination. Neurol Sci. 2021;42:1\u20132. https:\/\/doi.org\/10.1007\/s10072-021-05504-8.","journal-title":"Neurol Sci"},{"issue":"5","key":"1247_CR114","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ana.26065","volume":"89","author":"AL Goss","year":"2021","unstructured":"Goss AL, Samudralwar RD, Das RR, Nath A. ANA investigates: neurological complications of COVID-19 vaccines. Ann Neurol. 2021;89(5):856\u20137. https:\/\/doi.org\/10.1002\/ana.26065.","journal-title":"Ann Neurol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01247-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-022-01247-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01247-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:12:29Z","timestamp":1673395949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-022-01247-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s11910-022-01247-x","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"16 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aparajita Chatterjee and Ambar Chakravarty each declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}